• The modern concept of uterine cancer and its treatment
To content

The modern concept of uterine cancer and its treatment

HEALTH OF WOMAN.2016.7(113):16–22 

The modern concept of uterine cancer and its treatment 

Veropotvelyan P. N., Veropotvelyan N. P., Tsehmistrenko I. S., Bondarenko A. A.

The «Inter-provincial center of medical genetics and prenatal diagnosis», Krivoy Rog

Perinatal center, Kiev

Uterine fibroids – benign, monoclonal, well-demarcated, encapsulated tumors originating from the smooth muscle of the uterus or cervix cells in the body – one of the most common benign tumors. The emergence and development of uterine fibroids – a multifactorial process, which explains the frequent dissemination and heterogeneity of the tumor itself both morfogistohimicheskim characteristics and clinical manifestations. With the aim of preoperative preparation before removing nodes from patients’ symptomatic uterine myoma appointed agonist of gonadotropin-releasing hormone, progesterone antagonists (mifepristone). In the literature there are publications on the use of synthetic selective progesterone receptor modulator – ulipristal acetate not only for preoperative preparation of patients with uterine myoma, but also to their conservative therapy for 90 days. According to the result of a study conducted by the authors of the publication under the supervision of 11 patients with uterine myoma, reported a significant decrease in the size of fibroids in women surveyed 1/2. Despite the fact that the treatment of selective progesterone receptor modulator reduces the clinical manifestations and the growth of uterine fibroids, the efficacy and safety of its long-term use in patients with «symptomatic» myoma uteri nevertheless calls for further study

Key words: conservative treatment of uterine fibroids, progesterone receptor modulator, ulipristal acetate.


1. Levens ED, Potlog-Nahari C, Armstrong AY, Wesley R, Premku- mar A, Blithe DL. 2008. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet Gynecol. 111(5):1129–1136. http://dx.doi.org/10.1097/aog.0b013e3181705d0e

2. Nieman LK, Blocker W, Nansel T, Mahoney S, Reynolds J, Blithe D, Wesley R, Armstrong A. 2011. Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study. Fertil Steril. 95(2):767–772. http://dx.doi.org/10.1016/j.fertnstert.2010.09.059; PMid:21055739 PMCid:PMC4180231

3. Donnez J, Tatarchuk TF, Bouchard P. 2012. Ulipristal acetate versus placebo for fibroid treatment before surgery: REALT I Study Group. N Engl J Med. 366:409–420. http://dx.doi.org/10.1056/NEJMoa1103182; PMid:22296075

4. Popov АА, Machanskite OV, Manannikova TN. 2014. Surgical and medical treatment in reproduc- tive-aged patients with uterine myoma. Rossiiskii vestnik akushera-ginekologa. 14(5):111–114.

5. Barlow DH, Lumsden MA, Fauser BC, Terrill P, Bestel E. 2014. Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo. Hum Reprod. 29:480–489. http://dx.doi.org/10.1093/humrep/det467; PMid:24457604

6. Donnez J, Tatarchuk TF, Bouchard P, Puscasiu L, Zakharenko NF, Ivanova T, Ugocsai G, Mara M, Jilla MP, Bestel E, Terrill P, Osterloh I, Loumaye E. 2012. Ulipristal acetate versus placebo for fibroid treatment before surgery PEARL II Study Group. N Engl J Med. 366:421–429. http://dx.doi.org/10.1056/NEJMoa1103182http://dx.doi.org/10.1056/NEJMoa1103180; PMid:22296076

7. Donnez J, Vazquez F, Tomaszewski J, Nouri K, Bouchard P, Fauser BC, Barlow DH, Palacios S, Donnez O, Bestel E, Osterloh I, Loumaye E. 2014. PEARL III and PEARL III Extension Study Group. Long-term treatment of uterine fibroids with ulipristal acetate. Fertil Steril. 101:1565–1573. http://dx.doi.org/10.1016/j.fertnstert.2014.02.008; PMid:24630081

8. Luyckx M, Squifflet LJ, Jadoul P, Votino R, Dolmans MM, Donnez J. 2014. First series of 18 pregnancies after ulipristal acetate treatment for uterine fibroids. Fertil Steril. 102(5):1404–1409. http://dx.doi.org/10.1016/j.fertnstert.2014.07.1253; PMid:25241376

9. Czuczwar P, Wozniak S, Szkodziak P, Wrona W, Paszkowski T. 2014. Comparison of influence of ulipristal acetate and uterine artery embolization on fibroid volume and vascularity indices assessed by 3D ultrasound: a prospective observational study. Ultrasound Obstet Gynecol. 44:360. http://dx.doi.org/10.1002/uog.14581

10. Nagy B, Timar G, Jozwiak-Hagymasy J, Kovacs G, Meresz G, Vamossy I, Agh T, Laszlo A, Voko Z, Kalo Z. 2014. The cost-effectifeness of ulipristal acetate tablets in treating patients with moderate to severe symptoms of uterine fibroids. Eur J Obstet Gynecol Reprod Biol. 175:75–81. http://dx.doi.org/10.1016/j.ejogrb.2014.01.022; PMid:24568866

11. Zaidieva YAZ, Glazkova VA. 2016. Treatment in patients with uterine myoma: Facts and unsolved problems. Rossiiskii vestnik akushera- ginekologa 16(2):37–41. http://dx.doi.org/10.17116/rosakush201616237-41

12. Qi L, Nassir R, Kosoy R, Garcia L, Waetjen L, Ochs-Balcom HM, Gass M, Robbins J, Seldin MF. 2013. Relationship between hysterectomy and admixture in African American women. Am J Obstet Gynecol. 208(279):1–7. http://dx.doi.org/10.1016/j.ajog.2013.01.027

13. Lupez FR, Ornat L, Ceausu I, Depypere H, Erel CT, Lambrinoudaki I, Schenck-Gustafsson K, Simoncini T, Tremollieres F, Rees M. 2014. EMAS position Statement: management of uterine fibroids. Maturitas. 79:106–116. http://dx.doi.org/10.1016/j.maturitas.2014.06.002; PMid:24975954

14. Munro MG, Critchley HO, Broder MS, Fraser IS. 2011. FIGO Working Group on Menstrual Disorders. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet. 113:3–13. http://dx.doi.org/10.1016/j.ijgo.2010.11.011; PMid:21345435

15. Dreisler E, Poulsen LG, Antonsen SL, Ceausu I, Depypere H, Erel CT, Lambrinoudaki I, Pйrez-Lуpez FR. 2013. European Menopause and Andropause Society. EMAS clinical guide: assessment of the endometrium in peri and postmenopausal women. Maturitas. 75:181–190. http://dx.doi.org/10.1016/j.maturitas.2013.03.011; PMid:23619009

16. Patel A, Malik M, Britten J, Cox J, Catherino WH. 2014. Alternative therapies in management of leiomyomas. Fertil Steril. 102:649–655. http://dx.doi.org/10.1016/j.fertnstert.2014.07.008; PMid:25106764

17. Lethaby A, Vollenho-ven B. 2011. Fibroids (uterine myomatosis, leiomyomas). BMJ Clin Evid (Online). 2011:0814.

18. Bulun SE. 2013. Uterine fibroids. N Engl J Med. 369:1344–1355. http://dx.doi.org/10.1056/NEJMra1209993; PMid:24088094

19. Tal R, Segars JH. 2013. The role of angiogenic factors in fibroid pathogenesis: potential implications for future therapy. Hum Reprod Up- date. 20:194–216. http://dx.doi.org/10.1093/humupd/dmt042; PMid:24077979 PMCid:PMC3922145

20. Maruo T, Ohara N, Wang J, Matsuo H. 2004. Sex steroidal regulation of uterine leiomyoma growth and apoptosis. Hum Reprod Update. 10:207–220. http://dx.doi.org/10.1093/humupd/dmh019; PMid:15140868

21. Yamada T, Nakago S, Kurachi O, Yamada T, Nakago S, Kurachi O, Wang J, Takekida S, Matsuo H, Maruo T. 2004. Progesterone down- regulates insulin-like growth factor-I expression in cultured human uterine leiomyoma cells. Hum Reprod. 19:815–821. http://dx.doi.org/10.1093/humrep/deh146; PMid:15033949

22. Doherty L, Mutlu L, Sinclair D, Taylor H. 2014. Uterine fibroids: clinical manifestations and contemporary management. Reprod Sci. 21:1067–1092. http://dx.doi.org/10.1177/1933719114533728; PMid:24819877

23. Sangkomkamhang US, Lumbiganon P, Laopai-boon M, Mol BW. 2013. Progestogens or progestogen-releasing intrauterine systems for uterine fibroids. Cochrane Database Syst Rev. 2:CD008994. http://dx.doi.org/10.1002/14651858.cd008994.pub2

24. U.S. Food and Drug Administration. FDA Drug Safety Communication: Ongoing safety review of GnRH agonists and possible increased risk of diabetes and certain cardiovascular diseases. 2010, May 3.

25. Zhang Y, Sun L, Guo Y, Huang Z, Zhu T, Gu J, He Y, Wang W. 2014. The impact of preoperative gonadotropin-releasing hormone agonist treatment on women with uterine fibroids: a meta-analysis. Obstet Gynecol Surv. 69:100–108. http://dx.doi.org/10.1097/OGX.0000000000000036; PMid:25112488

26. Yerushalmi GM, Gilboa Y, Jakobson-Setton A, Tadir Y, Goldch- mit C, Katz D, Seidman DS. 2014. Vaginal mifepristone for the treatment of symptomatic uterine leiomyomata: an open-label study. Fertil Steril. 101:496–500. http://dx.doi.org/10.1016/j.fertnstert.2013.10.015; PMid:24220703

27. Shen Q, Hua Y, Jiang W, Zhang W, Chen M, Zhu X. 2013. Effects of mifepristone on uterine leiomyoma in premenopausal women: a meta-analysis. Fertil Steril. 100:1722–1726. http://dx.doi.org/10.1016/j.fertnstert.2013.08.039; PMid:24094421

28. Engman M, Varghese S, Lagerstedt Robinson K, Malmgren H, Hammarsjo A, Bystrom B, Lalitkumar PG, Gemzell-Danielsson K. 2013. GSTM1 gene expression correlates to leiomyoma volume regression in response to mifepristone treatment. PLoS One. 8:e80114. http://dx.doi.org/10.1371/journal.pone.0080114; PMid:24324590 PMCid:PMC3851176

29. Richardson AR, Maltz FN. 2012. Ulipristal acetate: review of the efficacy and safety of a newly approved agent for emergency contraception. Clin Ther. 34:24–36. http://dx.doi.org/10.1016/j.clinthera.2011.11.012; PMid:22154199

30. Brazert M, Korman MP, Pawelczyk LA. 2013. Applicability of selective progesterone receptor modulators in the treatment of uterine leiomyomata and their future role in the field of gynecology. Ginekol Pol. 84:794–800. http://dx.doi.org/10.17772/gp/1642; PMid:24191519

31. Attardi BJ, Burgenson J, Hild SA, Reel JR, Blye RP. 2002. CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914. Mol Cell Endocrinol. 188:111–123. http://dx.doi.org/10.1016/S0303-7207(01)00743-2

32. Blithe DL, Nieman LK, Blye RP, Stratton P, Passaro M. 2003. Devel opment of the selective progesterone receptor modulator CDB – 2914 for clinical indications. Steroids 68:1013–1017. http://dx.doi.org/10.1016/S0039-128X(03)00118-1

33. Horak P, Mara M, Dundr P, Kubinova K, Kuzel D, Hudecek R, Chmel R. 2012. Effect of a selective progesterone receptor modulator on induction of apoptosis in uterine fibroids in vivo. Int J Endocrinol. Article ID 436174. http://dx.doi.org/10.1155/2012/436174; PMid:22844281 PMCid:PMC3403220

34. Shimomura Y, Matsuo H, Samoto T, Maruo T. Up-Regulation by progesterone cell nuclear antigen and epidermal growth factor expression in human uterine leiomyoma. J Clin Endocrin Metab. 83:6.

35. Schwartz S, Voigt L, Tickman E et al. 2000. Familial aggregation of uterine leiomyomata. Am J Epidemiol. 151:10.

36. Marshall LM, Spiegelman D, Goldman M et al. 1998. A prospective study of reproductive factors and oral contraceeptive use in relation to the risk of uterine leiomyomata. Fertil Steril. 70:432–439. http://dx.doi.org/10.1016/S0015-0282(98)00208-8